Srivastava Sapna

SEC source: 0001193125-26-305082 · ownership.xml · derivative · entry 7

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 4,147 shares

Expires 2035-06-18

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

SEC source: 0001193125-26-305082 · ownership.xml · derivative · entry 6

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 3,789 shares

Expires 2034-06-12

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

SEC source: 0001193125-26-305082 · ownership.xml · derivative · entry 5

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 15,000 shares

Expires 2033-06-15

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

SEC source: 0001193125-26-305082 · ownership.xml · derivative · entry 4

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 20,000 shares

Expires 2032-06-16

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

SEC source: 0001193125-26-305082 · ownership.xml · derivative · entry 3

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 68,500 shares

Expires 2031-07-28

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

SEC source: 0001193125-26-305082 · ownership.xml · nonDerivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · kind: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.

F4 · kind: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

F4 · shares: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

F4 · price: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

SEC source: 0001193125-26-305082 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.

F2 · kind: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F1 · shares: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.

F2 · shares: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.

F2 · price: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

SEC source: 0001569226-26-000005 · form4-07022026_100741.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2036-06-29

F2 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001569226-26-000005 · form4-07022026_100741.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,553

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001569226-26-000002 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,590

F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001193125-26-271170 · ownership.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-11

F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

SEC source: 0001193125-26-271170 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,500

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

SEC source: 0001569226-25-000005 · form4-10282025_061017.xml · derivative · entry 4

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,800 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

SEC source: 0001569226-25-000005 · form4-10282025_061017.xml · derivative · entry 3

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

SEC source: 0001569226-25-000005 · form4-10282025_061017.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

SEC source: 0001569226-25-000005 · form4-10282025_061017.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F2 · price: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share.

SEC source: 0001415889-25-020835 · form4-08012025_040805.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,800

Underlying: Common Stock · 49,800 shares

Expires 2035-07-29

F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0000950170-25-088551 · ownership.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,147

Underlying: Class A Common Stock · 4,147 shares

Expires 2035-06-18

F2 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of June 18, 2026 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0000950170-25-088551 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,146

F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 18, 2026 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0000950170-25-087891 · ownership.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2035-06-17

F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

SEC source: 0000950170-25-087891 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,500

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

SEC source: 0001827506-25-000080 · wk-form4_1749242156.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2035-06-04

F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001415889-24-018606 · form4-07012024_080705.xml · derivative · entry 5

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,946

Underlying: Common Stock · 29,946 shares

Expires 2032-05-24

F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock.

F3 · derivative.exercise_date: Option vests in 36 equal monthly installments from May 24, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001415889-24-018606 · form4-07012024_080705.xml · derivative · entry 4

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 29,946 shares

Expires 2032-05-24

F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock.

F3 · derivative.exercise_date: Option vests in 36 equal monthly installments from May 24, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001415889-24-018606 · form4-07012024_080705.xml · derivative · entry 3

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,877

Underlying: Common Stock · 28,877 shares

Expires 2034-06-26

F1 · kind: Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.

F1 · derivative.exercise_date: Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001415889-24-018606 · form4-07012024_080705.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 28,877 shares

Expires 2034-06-26

F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock.

F1 · derivative.exercise_date: Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001415889-24-018606 · form4-07012024_080705.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,877

Underlying: Class A Common Stock · 28,877 shares

Expires 2034-06-26

F1 · derivative.exercise_date: Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0000950170-24-076713 · ownership.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,500

Underlying: Common Stock · 14,500 shares

Expires 2034-06-20

F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

SEC source: 0000950170-24-076713 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,500

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

SEC source: 0001104659-24-073456 · tm2417570-6_4seq1.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 10,000 shares

Expires 2034-06-16

F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.

SEC source: 0001104659-24-073456 · tm2417570-6_4seq1.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,096

F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.

SEC source: 0000950170-24-073679 · ownership.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,789

Underlying: Class A Common Stock · 3,789 shares

Expires 2034-06-12

F2 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of June 12, 2025 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0000950170-24-073679 · ownership.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,499

F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 12, 2025 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001827506-24-000053 · wk-form4_1717790553.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-04

F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001209191-23-053407 · doc4.xml · derivative · entry 3

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-10-22

F3 · derivative.exercise_date: The shares subject to the option vest in substantially equal monthly installments over a three-year period measured from one month following October 23, 2023, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001209191-23-053407 · doc4.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,500 shares

Expires 2033-06-13

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Tourmaline Bio, Inc., the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer, the Reporting Person's stock option to purchase 20,500 shares of Common Stock of the Issuer (prior to giving effect to the reverse stock split described below) was accelerated and cancelled at the effective time of the merger contemplated by the Merger Agreement. In consideration for such cancellation, the Reporting Person received a cash payment of $8,066 and 518 shares of Common Stock (after giving effect to a 10-for-1 reverse stock split of the Issuer's Common Stock effected immediately prior to the effective time of the merger).

F2 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.

SEC source: 0001209191-23-053407 · doc4.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 518

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Tourmaline Bio, Inc., the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer, the Reporting Person's stock option to purchase 20,500 shares of Common Stock of the Issuer (prior to giving effect to the reverse stock split described below) was accelerated and cancelled at the effective time of the merger contemplated by the Merger Agreement. In consideration for such cancellation, the Reporting Person received a cash payment of $8,066 and 518 shares of Common Stock (after giving effect to a 10-for-1 reverse stock split of the Issuer's Common Stock effected immediately prior to the effective time of the merger).

F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Tourmaline Bio, Inc., the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer, the Reporting Person's stock option to purchase 20,500 shares of Common Stock of the Issuer (prior to giving effect to the reverse stock split described below) was accelerated and cancelled at the effective time of the merger contemplated by the Merger Agreement. In consideration for such cancellation, the Reporting Person received a cash payment of $8,066 and 518 shares of Common Stock (after giving effect to a 10-for-1 reverse stock split of the Issuer's Common Stock effected immediately prior to the effective time of the merger).

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Tourmaline Bio, Inc., the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer, the Reporting Person's stock option to purchase 20,500 shares of Common Stock of the Issuer (prior to giving effect to the reverse stock split described below) was accelerated and cancelled at the effective time of the merger contemplated by the Merger Agreement. In consideration for such cancellation, the Reporting Person received a cash payment of $8,066 and 518 shares of Common Stock (after giving effect to a 10-for-1 reverse stock split of the Issuer's Common Stock effected immediately prior to the effective time of the merger).

SEC source: 0001209191-23-037847 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Class A Common Stock · 15,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of June 15, 2024 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001209191-23-037388 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,875

Underlying: Common Stock · 39,875 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

SEC source: 0001209191-23-037193 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.

SEC source: 0000899243-23-015203 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0001104659-23-064215 · tm2316873-6_4seq1.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 10,000 shares

Expires 2033-05-21

F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.

SEC source: 0001104659-23-064215 · tm2316873-6_4seq1.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,173

F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.

SEC source: 0001209191-22-037861 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Class A Common Stock · 20,000 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of June 16, 2023 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001209191-22-037480 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

SEC source: 0000899243-22-023127 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-022243 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,501

Underlying: Common Stock · 14,501 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.

SEC source: 0000899243-21-042075 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2031-10-27

F1 · derivative.exercise_date: The shares underlying this option vest as follows: These shares will vest in full on October 28, 2022.

SEC source: 0000899243-21-030832 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,500

Underlying: Class A Common Stock · 68,500 shares

Expires 2031-07-28

F1 · derivative.exercise_date: The shares underlying this option vest over the next three years in equal monthly installments following July 28, 2021, subject to continued service to the Company through the applicable vesting date.

SEC source: 0001209191-21-041539 · doc4.xml · derivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 10,500 shares

Expires 2031-06-14

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 15, 2022 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders following the date of grant, in each case subject to the Reporting Person's continued service on the Board.